TipRanks on MSN

Ocular Therapeutix announces first patient randomized in HELIOS-3 program

Ocular Therapeutix (OCUL) announced that the first patient has been randomized in the HELIOS-3 Phase 3 registrational program for AXPAXLI for the ...
PE Hub

Helios to close third Africa-focused fund at $1.1 bln

Helios Investments Partners will soon be closing its third Africa-focused fund at a hard cap of $1.1 billion, beating its $1 billion target. The LPs for Helios III include sovereign wealth funds, ...
Business Daily Africa

Equity’s part owner Helios raises Sh100bn for continent

Helios, a Pan-African private equity firm, has raised $1.1 billion (Sh100 billion) — one of the largest amounts ever — for an Africa-focused fund. Helios III fund said it had managed to raise $1.1 ...
News Medical

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Today, Pharmacyclics LLC announced the results of the Phase III HELIOS trial (CLL3001), which found that patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic ...
BioWorld

Chariot to admire: Alnylam finds place in sun with Helios-A phase III

Alnylam Pharmaceuticals Inc. said the 164-patient Helios-A phase III study with next-generation RNAi drug vutrisiran hit its primary endpoint as well as both secondary goals in the treatment of ...